Focus on translating the microbiome

In this issue - pvii

doi:10.1038/nbt.2562

Full Text - In this issue | PDF - In this issue

Focus on translating the microbiome

Laying better plans for mice - p263

doi:10.1038/nbt.2560

Genetically defined germ-free animal models colonized with defined microbiota are crucial for progress in microbiome research.

Abstract - | Full Text - Laying better plans for mice | PDF - Laying better plans for mice

Focus on translating the microbiome

Trends in microbiome research - p277

Susan Jones

doi:10.1038/nbt.2546

Full Text - Trends in microbiome research | PDF - Trends in microbiome research

Focus on translating the microbiome

The startup bugs - pp279 - 281

Charles Schmidt

doi:10.1038/nbt.2544

Burgeoning research on the human microbiome is facilitating the development of more mechanistically driven probiotics. Charles Schmidt investigates a smattering of probiotic- and microbiota-modifying therapeutic opportunities arising from commercial efforts.

Abstract - | Full Text - The startup bugs | PDF - The startup bugs

Focus on translating the microbiome

A snapshot of the microbiome field - pp282 - 283

Susan Jones

doi:10.1038/nbt.2545

A survey of leading scientists from academia and industry highlights notable papers that have garnered momentum in microbiome research.

Abstract - | Full Text - A snapshot of the microbiome field | PDF - A snapshot of the microbiome field

Focus on translating the microbiome

Translating the human microbiome - pp304 - 308

James Brown, Willem M de Vos, Peter S DiStefano, Joël Doré, Curtis Huttenhower, Rob Knight, Trevor D Lawley, Jeroen Raes & Peter Turnbaugh

doi:10.1038/nbt.2543

Nine experts discuss the challenges in translating current research on the human microbiome into strategies for disease prediction, diagnosis and therapy.

Abstract - | Full Text - Translating the human microbiome | PDF - Translating the human microbiome

Focus on translating the microbiome

Medicines from microbiota - pp309 - 315

Bernat Olle

doi:10.1038/nbt.2548

Five years after the launch of the Human Microbiome Project, several ventures are seeking to capitalize on the clinical promise of microbiome modulation. Commercialization of drugs that influence the human flora poses some unique scientific, translational and regulatory challenges.

Abstract - | Full Text - Medicines from microbiota | PDF - Medicines from microbiota

Focus on translating the microbiome

Recent patent applications in bacteriotherapy - p318

doi:10.1038/nbt.2559

Full Text - Recent patent applications in bacteriotherapy | PDF - Recent patent applications in bacteriotherapy